Landscapes / Companies
TG Therapeutics, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 6 in all
Trials
8 active
32 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
CD20-directed cytolytic antibody |
Approved | 21 Jan 2027Phase 3 trial completes | |||
| How it works | An antibody that marks B cells (a type of immune cell) for destruction | ||||
| Next date | 21 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS) and 3 more | ||||
| Open drug page | |||||
Gene therapy substances |
Phase 1 | 1 Dec 2026soonPhase 1 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | 1 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | B-cell Mediated Autoimmune Disorders | ||||
| Open drug page | |||||
About
- No active trial
- Cosibelimab, SHR1459, TG-1801, TGR-1202
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021